| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/17/2001 | WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 05/17/2001 | WO2001007602A3 Oligonucleotides for inhibiting the expression of human eg5 |
| 05/17/2001 | WO2001002593A3 Control of gene expression in eukaryotic cells |
| 05/17/2001 | WO2001000662A3 The use of human fgh-8 polypeptides as neurotrophic agents |
| 05/17/2001 | WO2000077166A3 Gene expression modulated in gastrointestinal inflammation |
| 05/17/2001 | WO2000049038A9 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof |
| 05/17/2001 | WO2000030671A9 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 05/17/2001 | WO2000024755A9 Ovary-specific genes and proteins |
| 05/17/2001 | DE19954376A1 Culturing of cells, particularly neuronal cells, useful for transplantation for treating neurological disorders such as Parkinson's disease or for gene therapy |
| 05/17/2001 | DE19953732A1 New human virus-inhibiting peptide, useful e.g. for treating viral or other infections or cancer, comprises fragment of alpha1-antitrypsin |
| 05/17/2001 | DE19952983A1 Verfahren zum Transfer von molekularen Substanzen mit prokaryontischen nukleinsäurebindenden Proteinen A method for the transfer of molecular substances with prokaryotic nucleic acid binding proteins |
| 05/17/2001 | DE19952982A1 Verfahren zur gerichteten Verpackung von molekularen Substanzen in Proteinhüllen Method for the directed packaging of molecular substances in protein shells |
| 05/17/2001 | DE19952957A1 Modulare Transportsysteme für molekulare Substanzen und deren Herstellung und Verwendung Modular Transport systems for molecular substances and their production and use |
| 05/17/2001 | CA2428827A1 Human vanilloid receptor gene |
| 05/17/2001 | CA2391369A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 05/17/2001 | CA2391129A1 Lentiviral vector transduction of hematopoietic stem cells |
| 05/17/2001 | CA2390999A1 Induction of mucosal immunity by vaccination via the skin route |
| 05/17/2001 | CA2390995A1 Recombinant gelatin in vaccines |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2390374A1 Diagnosis and treatment of malignant neoplasms |
| 05/17/2001 | CA2389954A1 Method of inducing angiogenesis |
| 05/17/2001 | CA2389724A1 28 human secreted proteins |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389550A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/17/2001 | CA2389524A1 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 05/17/2001 | CA2389506A1 Nucleic acid-containing complex |
| 05/17/2001 | CA2389488A1 Isolation and expansion of human marrow stromal cells |
| 05/17/2001 | CA2389330A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2389305A1 28 human secreted proteins |
| 05/17/2001 | CA2388914A1 15 human secreted proteins |
| 05/17/2001 | CA2388912A1 6 human secreted proteins |
| 05/17/2001 | CA2388643A1 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | CA2388477A1 Recombinant gelatins with uniform molecular weight |
| 05/17/2001 | CA2388019A1 24 human secreted proteins |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2359955A1 Human vanilloid receptor gene |
| 05/17/2001 | CA2325226A1 Use of polypeptides or nucleic acids encoding these for the diagnosis or treatment of skin disorders, and their use for the identification of pharmacologically active substances |
| 05/16/2001 | EP1099754A1 Mesenchymal stem cells and/or progenitor cells, their isolation and use |
| 05/16/2001 | EP1098986A2 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe) |
| 05/16/2001 | EP1098985A1 Genes of the dead box protein family, their expression products and use |
| 05/16/2001 | EP1098970A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors |
| 05/16/2001 | EP1098969A2 Use of nucleic acid molecules as antiviral agents |
| 05/16/2001 | EP1098968A2 Nitrilase homologs |
| 05/16/2001 | EP1098904A1 Axor10, a g-protein coupled receptor |
| 05/16/2001 | EP1098667A1 Chelating systems for use in the delivery of compounds to cells |
| 05/16/2001 | EP1098664A2 Conjugates for treating inflammatory disorders and associated tissue damage |
| 05/16/2001 | EP1098661A2 Gnrh vaccines for suppressing reproductive behavior in animals |
| 05/16/2001 | EP1098632A1 Charge reversal of polyion complexes |
| 05/16/2001 | EP1084709A9 Oral recombinant lactobacilli vaccines |
| 05/16/2001 | EP0994948B1 Tgf beta rii receptor nucleic sequence, coded peptide, and uses |
| 05/16/2001 | CN1295617A Variants of angiogenic factor vascular endothelial cell growth factor: VEGF |
| 05/16/2001 | CN1295616A Tumor-associated antigen derivatives from MAGE family, and nucleic acid sequence encoding them |
| 05/16/2001 | CN1295615A Human p51 genes and gene products thereof |
| 05/16/2001 | CN1295614A Modulator for function of receptor of TNF/NGF receptor family and other protein |
| 05/16/2001 | CN1295612A Mutant herpes simplex viruses and uses thereoe |
| 05/16/2001 | CN1295580A Method for producing mouse and haman endogenous vascular formation inhibition factor |
| 05/16/2001 | CN1295579A Therapeutic uses of keratinocyte growth factor-2 |
| 05/15/2001 | US6232523 To study tumor progresssion in vertebrates; stably transformed tumor cell line transfected with expression vector nucleotide sequence under control of viral promoter; continued expression through cell line proliferation |
| 05/15/2001 | US6232460 Isolated nucleic acid molecule which encodes an SCP-1 mutein |
| 05/15/2001 | US6232459 Synaptojanin isoform |
| 05/15/2001 | US6232454 Nucleic acid and amino acid sequences and use in diagnosis, treatment, and prevention of cancer and immune disorders |
| 05/15/2001 | US6232452 Autosomal dominant disorder of growths in many tissues and organs identified on chromosome 16 deletion mutations; use in disease diagnosis and screening; the gene may behave as a tumor suppressor |
| 05/15/2001 | US6232449 Persephin and related growth factors |
| 05/15/2001 | US6232443 Useful markers in diagnosing and monitoring cancerous renal cells; detecting cell proliferative disorders |
| 05/15/2001 | US6232441 PIGR-1, a member of immunoglobulin gene superfamily |
| 05/15/2001 | US6232296 Administering oligonucleotide with one or more phosphorothioate modifications |
| 05/15/2001 | US6232295 Cell-specific contrast agent and gene delivery vehicles |
| 05/15/2001 | US6232289 Method of treating interstitial cytitis with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF) |
| 05/15/2001 | US6232120 Methods to inhibit replication of infective virus |
| 05/15/2001 | US6232119 Immortalized human fetal neuronal cell line |
| 05/15/2001 | US6232105 Conditional replication and expression system |
| 05/15/2001 | US6232097 Nucleotide sequences coding enzymatic polypeptide; prevent bacterial infection; wound healing agents; for vaccine development |
| 05/15/2001 | US6232077 Genetic engineering and expression; cancer diagnosis |
| 05/15/2001 | US6232064 Fibrosis and atherosclerosis determination |
| 05/15/2001 | US6231879 Implantable, biocompatible cell encapsulation with jackets |
| 05/15/2001 | US6231863 DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same |
| 05/15/2001 | US6231854 Methioninase formulations and use in diagnostic methods |
| 05/10/2001 | WO2001033223A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001032926A2 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | WO2001032925A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | WO2001032923A1 Antisense inhibition of pi3 kinase p55 gamma expression |
| 05/10/2001 | WO2001032920A2 Agents implicated in endometriosis |
| 05/10/2001 | WO2001032901A1 Expression vectors, transfection systems, and method of use thereof |
| 05/10/2001 | WO2001032900A1 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 05/10/2001 | WO2001032898A2 Recombinant sendai virus vector for introducing exogenous genes to airway epithelia |
| 05/10/2001 | WO2001032891A2 Human lipase |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032885A2 Human lipase |
| 05/10/2001 | WO2001032878A2 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | WO2001032873A1 Insulin-responsive sequence dna binding protein-1' (irsdbp-1), gene encoding it and uses thereof |
| 05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032863A1 A novel polypeptide, a human apoptosis associated protein 12 and the polynucleotide encoding the polypeptide |
| 05/10/2001 | WO2001032859A1 Novel tumor suppressor gene |
| 05/10/2001 | WO2001032852A2 Method for directed packaging of molecular substances in protein shells |